Vitamin D receptor activation and survival in chronic kidney disease  by Kovesdy, C.P. & Kalantar-Zadeh, K.
Vitamin D receptor activation and survival in chronic
kidney disease
CP Kovesdy1,2 and K Kalantar-Zadeh3,4
1Division of Nephrology, Salem Veterans Affairs Medical Center, Salem, Virginia, USA; 2Department of Medicine, University of Virginia,
Charlottesville, Virginia, USA; 3Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Research
Institute at Harbor-UCLA Medical Center, Torrance, California, USA and 4David Geffen School of Medicine at UCLA, Los Angeles,
California, USA
Replacement of activated vitamin D has been the
cornerstone of therapy for secondary hyperparathyroidism
(SHPT). Recent findings from several large observational
studies have suggested that the benefits of vitamin D
receptor activators (VDRA) may extend beyond the
traditional parathyroid hormone (PTH)-lowering effect, and
could result in direct cardiovascular and metabolic benefits.
The advent of several new analogs of the activated vitamin D
molecule has widened our therapeutic armamentarium, but
has also made therapeutic decisions more complicated.
Treatment of SHPT has become even more complex with the
arrival of the first calcium-sensing receptor (CSR) agonist
(cinacalcet hydrochloride) and with the uncovering of novel
mechanisms responsible for SHPT. We provide a brief
overview of the physiology and pathophysiology of SHPT,
with a focus on vitamin D metabolism, and discuss various
practical aspects of VDRA therapy and its reported
association with survival in recent observational studies.
A detailed discussion of the available agents is aimed at
providing the practicing physician with a clear understanding
of the advantages or disadvantages of the individual
medications. A number of open questions are also analyzed,
including the present and future roles of CSR agonists and
25(OH) vitamin D replacement.
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Disorders of mineral and bone metabolism are common in
patients with chronic kidney disease (CKD)1 and have been
implicated as a novel risk factor in the high mortality seen
in this patient population.2,3 These encompass not only
conditions related to the traditionally defined renal osteody-
strophy, including secondary hyperparathyroidism (SHPT),
disorders of vitamin D metabolism, hyperphosphatemia, and
hypo- and hypercalcemia, but also more recently defined
disease states related to vascular calcification. Due to this
wide range of complications, the more inclusive term CKD
mineral and bone disorder (CKD-MBD) is currently
favored.4 Several of the abnormalities characterizing CKD-
MBD have been amenable to therapeutic interventions, and
have hence become a cornerstone of our day-to-day
management of patients with CKD. One of these is SHPT,
which is due in part to the progressive decline in activated
vitamin D levels with advancing stages of CKD.1,5 Replace-
ment of activated vitamin D has thus become the main
strategy in the treatment of SHPT. The introduction of a
number of analogs of the activated vitamin D molecule,
together known as vitamin D receptor activators (VDRA),
has broadened our therapeutic armamentarium,6,7 but has
also made decisions about which drug to use more
complicated. We examine the rationale for the therapeutic
use of activated vitamin D, provide an overview of the effects
of various available analogs of activated vitamin D, and
summarize the available scientific evidence supporting the
use of them, alone or in combination with other therapeutic
agents such as calcium-sensing receptor (CSR) agonists or
25(OH) vitamin D. In particular, we review the recent
observational data on the association of VDRA and survival
in CKD and expand our discussion on interpretation of such
associative data in the setting of clinical practice and current
and anticipated treatment guidelines.
SHPT AND VITAMIN D METABOLISM
SHPT develops early in the course of CKD as a result of a
combination of the following events: deficiency of 1,25-
dihydroxycholecalciferol (activated vitamin D),1,5 decreased
expression of the vitamin D receptor8 and the CSR,9
hyperphosphatemia,10 hypocalcemia,11 and PTH resistance.12
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More recently, fibroblast growth factor 23 has emerged as a
new regulator that plays an important role in CKD-MBD.13
Fibroblast growth factor 23, like PTH, has phosphaturic
properties, but, unlike PTH, it inhibits 1-a-hydroxylation
and hence leads to lower levels of activated vitamin D and
further stimulation of PTH production.13 Additionally,
fibroblast growth factor 23 may have a direct stimulatory
effect on the parathyroid glands, hence further contributing
to SHPT.14 As kidney function declines in patients with CKD,
their PTH levels become increasingly higher, mirrored by a
progressive decline in activated vitamin D levels.1 It is unclear
to what extent these different pathophysiological mechanisms
(intrinsic loss of enzymatic activity vs. suppression by
fibroblast growth factor 23) contribute to the lower 1-a-
hydroxylase activity, but the net effect is a progressive decline
in activated vitamin D levels with advancing stages of CKD.1
Administration of synthetic activated vitamin D to replace
physiological levels of this hormone thus appears to be a
plausible strategy to treat SHPT. The application of activated
vitamin D in physiological doses often fails to correct SHPT,
in part due to decreased expression of the vitamin D receptor
in the parathyroid gland.8 This can be overcome by the
administration of higher doses of activated (1,25(OH)2)
vitamin D, but such pharmacological doses are more likely to
induce side effects. Most relevant of these undesirable side
effects are hypercalcemia and hyperphosphatemia,15 which
have themselves been associated with higher mortality in
patients on dialysis.2,3 To circumvent such side effects, new
agents have been developed that showed a more selective
effect toward suppressing PTH production, with a lesser
effect on intestinal and bone absorption of calcium and
phosphorus.16,17 These novel analogs of activated vitamin D
(paricalcitol and doxercalciferol in the United States and
alpha-calcidol and maxacalcitol outside the United States)
appeared to have less effects on the vitamin D receptors in the
gastrointestinal tract and bone, thus mitigating calcium and
phosphorus absorption and allowing a wider therapeutic
margin. Nevertheless, the concept of VDRA selectivity and its
utility in clinical practice has been a matter of ongoing
debate.18
THE CASE FOR VDRA: BENEFITS BEYOND LOWERING OF PTH?
While the only current indication for the use of activated
vitamin D and its analogs in patients with CKD is the
treatment of SHPT, the impact of lowering PTH levels may
extend beyond the skeletal system and includes potential
cardiovascular and metabolic benefits.2,3,19 This has
prompted a number of large observational studies examining
outcomes associated with the use of activated vitamin D
therapy in patients on maintenance dialysis,3,20–24 and in
patients with CKD not yet on dialysis25 (Table 1). These
studies incorporated data from a very large number of
patients and consistently showed that patients treated with
any kind of VDRA experienced significantly lower all-cause
and cardiovascular mortality rates compared with patients
not receiving any treatment.
The most obvious explanation for the observed benefits
could be the effects induced by the lowering of PTH level
(Figure 1). Elevated PTH has been shown to induce a number
of cardiovascular (myocardial fibrosis, left-ventricular hyper-
trophy, decreased myocardial contractility, increased vascular,
and valvular calcification, decreased vasodilatation),26,27
metabolic (decreased insulin sensitivity and disorders of
lipid metabolism),28–30 hematological (bone marrow fibrosis
and decreased erythropoiesis),31,32 and immunological33
abnormalities. Treatment of SHPT could thus improve or
reverse a number of these abnormalities, potentially translat-
ing into a better survival.
On the other hand, the broad benefits observed in the
studies shown in Table 1 suggest that the impact of VDRA
reaches beyond lowering of PTH levels. Subgroup analyses in
these studies indicated that virtually all patients benefited
Table 1 | Observational studies examining outcomes associated with treatment of activated vitamin D compared with no
treatment in patients with CKD
Study
Number of
patients Examined treatment Results Comments
Shoji et al.22 242 Oral alpha calcidol vs
no treatment
Lower cardiovascular mortality
with alpha calcidol treatment
Prevalent HD patients from Japan; all cause
mortality similar in the two groups
Teng et al.23 51 037 Any VDRA vs no
treatment
20% lower all-cause mortality in
the vitamin D group
Prevalent HD patients from a single
for-profit dialysis chain; benefit present in
48 of 49 examined subgroups
Melamed et al.21 1007 Calcitriol vs no
treatment
Lower all-cause mortality
associated with calcitriol use
Incident HD and PD patients from CHOICE
study
Kalantar-Zadeh et al.3
and Lee et al.20
58 058 Paricalcitol vs no
treatment
Lower all-cause mortality
associated with paricalcitol use
in time-dependent models
Prevalent HD patients from a single
for-profit dialysis chain. Benefit present in
all examined subgroups
Tentori et al.24 7731 Any VDRA vs no
treatment
Lower all-cause mortality with
activated vitamin D
Prevalent HD patients from a single
non-profit dialysis chain
Kovesdy et al.25 520 Calcitriol vs no
treatment
Lower all-cause mortality with
calcitriol
CKD stage 2–5, not yet on dialysis. Also
showed trend toward lower ESRD
incidence with calcitriol
CKD, chronic kidney disease; ESRD, end-stage renal disease; HD, hemodialysis; PD, peritoneal dialysis; VDRA, vitamin D receptor activator.
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from activated vitamin D therapy, including patients with
lower PTH or higher calcium or phosphorus levels.20,23
Furthermore, vitamin D deficiency was associated with
higher all-cause and cardiovascular mortality in a large
cohort of hemodialysis patients,34 and lower 1,25(OH)2
vitamin D levels have been associated with worsened
coronary calcification,35 also suggesting a PTH-independent
link between vitamin D and survival.
The vitamin D receptor is ubiquitous, and its stimulation
has been shown to have wide-ranging effects.6 Some of the
many physiological effects of vitamin D receptor activation
could explain how the administration of activated vitamin D
could directly impact on the cardiovascular system: by
regressing cardiac hypertrophy,36 by decreasing the activation
of the renin–angiotensin system,37 by inhibiting the produc-
tion of proteins implicated in arterial calcification,38–40 by
stimulating the production of proteins that are inhibitors of
arterial calcification,38,41 by inhibiting the production of
cytokines that are involved in calcification and atheroma
formation42,43 and stimulating the production of cytokines
that are inhibiting it,44,45 and by preventing thrombosis46
(Figure 1). Non-cardiovascular effects related to stimulation
of vitamin D receptor include increased production of
cathelicidine47 (suggesting anti-tuberculosis properties) and
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Figure 1 |Putative mechanisms of action responsible for the lower mortality associated with vitamin D receptor activation.
Kidney International (2008) 73, 1355–1363 1357
CP Kovesdy and K Kalantar-Zadeh: VDRA and CKD survival r ev iew
anticancer effects.48 Such effects could explain the
broad benefit seen with activated vitamin D therapy in
observational studies, independent of the abnormalities of
CKD-MBD.
All the above putative mechanisms of action form a
plausible explanation for why the administration of VDRA
was associated with lower mortality in observational studies.
Since the vast majority of the studies elucidating
the mechanism of action of VDR activation come from
non-human experimental studies, their extrapolation to
clinical practice will have to wait for proof by randomized
controlled trials (RCTs).
VDRA AND SURVIVAL IN CKD: ASSOCIATION OR CAUSALITY?
Examining therapeutic interventions in observational studies
is always subject to confounding bias, no matter how
rigorous the statistical adjustments are. Recent examples
where the results of observational studies were refuted by
RCTs49–51 serve as a cautionary tale against using observa-
tional data as final proof of a beneficial effect. A set of criteria
for making the leap from association to causation was
systematically presented in the 1965 article of Sir Austin
Bradford Hill, ‘The Environment and Disease: Association or
Causation’.52 As shown in Table 2, applying Hill’s criteria to
the available evidence on activated vitamin D therapy shows
that six of the nine criteria appear to be satisfied. One (dose
response) is not (although the reason for this could be
confounding by the higher PTH levels seen in those receiving
higher doses of activated vitamin D3), one needs more
research (specificity), and one (experimentation) requires
controlled trials. There also are novel epidemiological
techniques such as structural nested modeling, marginal
structural modeling, propensity-based matching, or instru-
mental variable analysis that can better account for time-
varying confounders and that are sometimes called ‘causal
models’.53–56 Such methodology was applied in the study by
Teng et al.,23 the results of which were concordant with the
studies’ that applied more conventional methodologies.
Nevertheless, a conclusive answer could only be provided
by an RCT.
WHICH VITAMIN D ANALOG IS THE BEST?
Disorders of CKD-MBD are complex and incorporate
conditions such as hyperphosphatemia and disorders in
calcium metabolism beside SHPT. Higher phosphorus and
calcium levels have been associated with increased mortality
in patients on dialysis;2,3 hyperphosphatemia has also been
associated with higher mortality57,58 and more progression of
kidney disease58–60 in patients with earlier stages of CKD.
Treatment with the native VDRA calcitriol effectively
suppresses SHPT, but can have less salutary effects by
inducing hyperphosphatemia and hypercalcemia. This has
prompted the development of several activated vitamin
D analogs that can suppress PTH production, with a
lesser concomitant hypercalcemic and hyperphosphatemic
effect.7,61–63
One question that arises is whether the salutary side effect
profile of these activated vitamin D analogs translates into
superior outcomes compared to patients receiving calcitriol?
If the benefit of activated vitamin D therapy is indeed broad
ranging and extends to patient groups with hyperpho-
sphatemia and hypercalcemia,3,23 the favorable side effect
Table 2 | Hill’s criteria for causal inference in epidemiological studies. The causality criteria are examined for treatment with
activated vitamin D
Criterion Definition/comments Applied to vitamin D treatment in CKD
1. Temporal
relationship
Exposure always precedes the outcome Treatment with activated vitamin D is followed by improved
survival
2. Strength of
association
The stronger the association, the more likely it is that the
relation is causal
Most studies indicate a strong association with better
survival
3. Dose response Increasing amount of exposure increases the risk
proportionally
Higher doses of paricalcitol and calcitriol not associated with
better survival compared with lower doses
4. Consistency of
results
The association is consistent when results are replicated in
studies in different settings using different methods
Consistent results in incident and prevalent patients, in
for-profit and not-for-profit dialysis chains, and in patients
from different countries
5. Biological
plausibility
The association agrees with currently accepted
understanding of pathological processes. However, studies
that disagree with established understanding of biological
processes may force a re-evaluation of accepted beliefs
The effects of vitamin D receptor activation on lowering PTH
and on various cardiovascular and metabolic processes
provide a plausible explanation for the beneficial effect of
activated vitamin D therapy
6. Experimentation The condition can be altered (prevented or ameliorated) by
an appropriate experimental regimen
Randomized controlled trials examining the benefit of
activated vitamin D therapy are missing
7. Specificity If possible, a single putative cause produces a specific effect It is currently unclear which one of the potential effects of
activated vitamin D is responsible for the observed benefits
8. Biological
coherence
The association is consistent with the natural history of the
disease
An improved cardiovascular risk profile (such as seen with
activation of the vitamin D receptor) should result in lower
mortality
9. Analogy There are similar associations in other populations or under
different settings
Treatment with 25(OH) vitamin D of patients with normal
kidney function is beneficial. Activated vitamin D is only used
therapeutically in patients with CKD
CKD, chronic kidney disease; PTH, parathyroid hormone.
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profile of the more selective drugs may not be that important.
On the other hand, the activated vitamin D analogs may be
different from calcitriol in ways other than their lesser
intestinal effects.64–66 The activation of the VDR is a complex
process that involves recruitment of a multitude of
coactivators and corepressors.67 Differential recruitment of
such elements distinguishes the gene activation profile seen
with VDR stimulation from paricalcitol and calcitriol,65
which could translate into significant differences in their
clinical effects. Supporting an advantage from activated
vitamin D analogs are animal models showing that
paricalcitol induced significantly less vascular calcification
compared to calcitriol.68,69
A more complicated picture is suggested by another
experimental model of 5/6 nephrectomized rats, showing that
animals treated with paricalcitol displayed significant reduc-
tions in endogenously produced activated vitamin D
(calcitriol) levels and showed increased perivascular fibrosis,
but also a higher density of intramyocardial capillaries.66
These results suggest that calcitriol and activated vitamin D
analogs may differ significantly in their ancillary effects.
While some of these ancillary effects (such as the effect on
calcium, phosphorus, vascular calcification and capillary
density) seem to favor the analogs (or rather specifically
paricalcitol), others may be beneficial to calcitriol (such as
the more severe perivascular fibrosis seen with paricalcitol
treatment). What is unclear from these pre-clinical results is
the effect of the various activated vitamin D molecules on
clinical outcomes in patients with CKD. Teng et al.70
examined such outcomes in a historical cohort of 67 399
patients on maintenance hemodialysis, and found that
treatment with paricalcitol was associated with a 16% lower
all-cause mortality compared to treatment with calcitriol
(Table 3).
Contrasting the foregoing findings, Tentori et al.24 com-
pared outcomes in patients receiving paricalcitol, doxercalci-
ferol, and calcitriol in 7731 maintenance hemodialysis
patients, and found no differences between the three groups
after adjustment for potential confounders. The reason for
the discrepant findings of these observational studies is
unclear; RCT are needed to settle this issue. Other benefits of
activated vitamin D analogs were suggested by studies
showing lower hospitalization rates in patients treated with
paricalcitol vs calcitriol.71 This may be one of the reasons why
a cost analysis suggested that the use of paricalcitol provided
cost-savings compared with calcitriol, in spite of its higher
price.72,73 Limitations inherent of observational data apply to
these studies as well, and short of an RCT their results can
also be only viewed as hypothesis-generating.
A different concern arises in patients with CKD who are
not yet on dialysis, where progressive loss of kidney function
represents an important outcome. Pharmacological doses of
calcitriol may hasten loss of kidney function through
induction of hypercalciuria or hyperphosphatemia;60,74 this
effect is not seen with lower doses of calcitriol,25,75,76 which
also have been associated with a trend toward slower
progression of kidney disease in patients with CKD stages 3
and 4.25,76 Hypercalciuria is also a lesser concern with
activated vitamin D analogs,77,78 of which paricalcitol has
also been shown to reduce proteinuria in patients with CKD
stages 3 and 4,79 and to attenuate renal interstitial fibrosis in
experimental obstructive nephropathy.80
For the time being, our clinical practice will have to be
directed by what the approved indications of these medica-
tions are (treatment of SHPT), and hence the choice of agent
(calcitriol vs analog VDRA) will continue to be driven by
patient tolerance, individual side effect profiles, and cost
considerations. In patients with CKD who are not yet on
dialysis, physiological doses of calcitriol may be able to
adequately control the less severe SHPT, without deleterious
side effects and with a potentially renoprotective effect;25,76 if
higher doses are necessary, activated vitamin D analogs
(especially paricalcitol) may be safer.
The second practical question pertains to the choice of
particular activated vitamin D analog. The two agents
available in the United States (paricalcitol and doxercalciferol)
were approved on the basis of their ability to lower PTH
with a more favorable side effect profile compared with that
of calcitriol,77,78,81–86 but they have different pharmacological
characteristics. There are currently very few head-to-head
comparison studies between these two agents. Paricalcitol
may have a more favorable side effect profile in experimental
animals, with lower calcium and phosphorus absorption,61
and lower vascular calcification.69,87 Doxercalciferol may hold
an advantage due to its longer half-life, leading to more
consistent bioavailability.7 The available clinical studies
comparing paricalcitol and doxercalciferol were underpow-
ered and have suboptimal study designs. One study found
Table 3 | Observational studies comparing outcomes associated with the use of various activated vitamin D products in
patients on dialysis
Study Number of patients Examined treatment Results Comments
Teng et al.70 67 399 Paricalcitol vs
calcitriol
16% lower all-cause mortality
with paricalcitol
Prevalent HD patients from a single for-profit
dialysis chain, benefit also present in patients who
switched treatments
Tentori et al.24 7731 Calcitriol vs
paricalcitol vs
doxercalciferol
No difference in all-cause
mortality between the three
groups after multivariable
adjustment
Prevalent HD patients from a single non-profit
dialysis chain
HD, hemodialysis.
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similar serum calcium and phosphorus levels with equivalent
doses of the two agents in a before–after design of 27 dialysis
patients.88 A second study, a 36-h crossover study in 13
dialysis patients, showed comparable PTH suppression with
high doses of these two agents, but significantly higher serum
phosphorus levels and calcium phosphorus products in
those receiving doxercalciferol.89
Regarding survival benefits, the only study comparing the
two agents was observational and found no difference in
outcomes between patients on maintenance hemodialysis
treated with the two drugs.24 Thus, there is currently
insufficient evidence to clearly distinguish one activated
vitamin D analog from the other in clinical practice, and
decisions about which one to use will be based most likely on
individual patient characteristics or practitioner preference.
Due to the complexity of VDR activation, it is possible that
differences between the various activated vitamin D analogs
are substantial and go beyond their immediately obvious
effects on serum PTH, calcium, and phosphorus. Better-
designed and head-to-head conducted clinical comparisons
are needed to determine which drug is superior in terms of
clinical end points, especially survival.
UNANSWERED QUESTIONS
Should all patients receive treatment with activated vitamin D?
Observational studies are unanimous in their findings that
patients receiving any kind of activated vitamin D have lower
mortality compared with those who do not (Table 1).3,20–25
This benefit may or may not be related to lowering of PTH,
but because treatment of SHPT is the only approved
indication for the different VDRA, it is unclear what an
optimal regimen would be to maximize patient survival. On
the basis of their PTH levels, a significant proportion of
patients do not receive treatment with VDRA because of
concerns related to over-suppression of PTH levels and
adynamic bone disease.90 Observational studies in patients
receiving maintenance dialysis support the current PTH
target levels recommended by the K-DOQI guidelines,91 in
that PTH levels below the recommended 150–300 pgml1
seem to be associated with poorer survival.3 Complementing
these findings, however, patients with low PTH levels who
were treated with VDRA in the same study had lower
mortality compared with those who did not.3 It is possible
that the higher mortality that is in general associated with
states of lower PTH level (and adynamic bone disease) is the
result of confounding by a state of malnutrition and
inflammation,92–94 in which case treatment with VDRA
would not necessarily lead to worsened outcomes, in spite of
further lowering of their PTH levels. This question could only
be answered satisfactorily by a clinical trial; short of such a
trial, the current practice of only administering VDRA
therapy for treatment of SHPT has to be favored.
What is the role of 25(OH) vitamin D replacement?
The natural precursor of activated vitamin D (that is,
1,25(OH)2) is 25(OH) vitamin D, and hence a deficiency of
the latter can play a role in the low activated vitamin D levels
seen in patients with CKD.95 Low 25(OH) vitamin D levels
are very common in patients with CKD,96 but while activated
vitamin D levels appear to decline progressively with
worsening kidney function, 25(OH) vitamin D levels do
not.1 This suggests that 1-a-hydroxylation in the kidneys may
be a more important determinant of activated vitamin D
levels rather than the availability of its precursor. 25(OH)
Vitamin D is able to suppress PTH production in vitro by
virtue of direct stimulation of the VDR and a slow tissue-
level 1-a-hydroxylation;97 the low affinity of 25(OH) vitamin
D to the VDR is presumably counterbalanced by its higher
plasma concentration. Indeed, a small observational study
examined the effect of 25(OH) vitamin D (ergocalciferol)
replacement on PTH levels in patients with stage 3 and 4
CKD and found this strategy to be somewhat successful only
in the subgroup with stage 3 CKD.98 Similar studies in
patients on dialysis have also questioned the effectiveness of
25(OH) vitamin D therapy in achieving suppression of SHPT
and resolution of bone histological changes.99
It is yet unclear what the longer-term outcomes of 25(OH)
vitamin D replacement might be. Lower 25(OH) vitamin D
levels were associated with significantly higher mortality in
an observational study of incident hemodialysis patients, but
subsequent treatment with activated vitamin D nullified this
association; replacement of 25(OH) vitamin D was not
performed and thus its effect could not be analyzed.34 Studies
examining replacement of 25(OH) vitamin D in patients with
no kidney disease support a beneficial effect on survival,100
but the results of these studies cannot be extrapolated to
patients with CKD, due to the differences in activated
vitamin D levels between these two populations. It is possible
that the benefits of 25(OH) vitamin D replacement are
partially independent of activated vitamin D, if 25(OH)
vitamin D indeed has roles other then being a mere precursor
to activated vitamin D.101–105 In this case, replacement of both
components could be beneficial, but this idea needs to
undergo formal testing. Such a combined application may
especially be beneficial in patients treated with activated
vitamin D analogs, the selectivity of which may prevent them
from compensating for abnormalities brought about by
25(OH) vitamin D (and consequently, calcitriol) deficiency.106
Can CSR agonists circumvent the need for VDRA in CKD?
The advent of CSR agonists has not only added another
weapon to our armamentarium against SHPT, but also has
made therapeutic decisions more complicated. The only CSR
agonist currently available for clinical use is cinacalcet; this
agent has been shown to effectively lower PTH levels and to
lower the risk of parathyroidectomy, fracture, and cardiovas-
cular hospitalization, along with improvements in self-
reported physical function and diminished pain.107,108
Patients treated with cinacalcet may develop hypocalcemia,
which has been severe in about 5% of dialysis patients
enrolled in a clinical trial examining the efficacy and safety
of this drug.108 Although the majority of the hypocalcemic
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episodes seen with cinacalcet therapy are asymptomatic,108
it is unclear what its long-term consequences are.
While cinacalcet was only approved in the United States
for SHPT treatment in patients on dialysis, its use in patients
with CKD not yet on dialysis has also been examined.
Findings from a clinical trial in this population indicated that
patients treated with cinacalcet developed not only hypo-
calcemia but also significant hyperphosphatemia (possibly
related to the diminished phosphaturic effect of the lower
PTH levels).109 Additional concern in patients with earlier
stages of CKD is the impact on kidney function of the
hypercalciuria that can be expected from an agonist of CSR,
this receptor being expressed in the thick ascending limb of
the loop of Henle and the distal nephron.110 These concerns
have prompted the recent cessation of the manufacturer’s
efforts to pursue an indication to treat SHPT with cinacalcet
in patients with CKD who are not yet on dialysis in the
United States, and to withdraw this indication in Canada.
Finally, still little is known about the impact of cinacalcet
on outcomes requiring longer follow-up, such as mortality.
A recently initiated clinical trial will be examining this question
in hemodialysis patients with SHPT, but its results are probably
a few years away.111 Given all these uncertainties, we believe it is
premature to think that CSR agonists can take over the role of
VDRAs in the treatment of SHPT. Cinacalcet could be a
valuable addition in patients who are not responding adequately
to or who are intolerant of higher doses of VDRA.
SUMMARY
Pharmacological administration of activated vitamin D has
become the main strategy in the treatment of SHPT. There is
a large volume of observational evidence suggesting a broader
beneficial effect of such treatments, which could be the result
of multiple non-skeletal functions modulated by the vitamin
D receptor. The lack of RCTs means that a broadening of the
indication of use for activated vitamin D is not yet possible.
Due to insufficient clinical data, no single activated vitamin
D product can claim to be uniformly superior to the others,
although a wider therapeutic window often prompts the use
of activated vitamin D analogs in patients requiring higher
doses of these medications. Currently available evidence
favors individualized treatment decisions when choosing a
particular type of activated vitamin D, where detailed
knowledge of each of the available agents allows the tailoring
of the therapeutic regimen to the individual patients’ needs.
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